Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
NCT ID: NCT01305148
Last Updated: 2015-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
NA
3800 participants
INTERVENTIONAL
2011-08-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clarification of Optimal Anticoagulation Through Genetics
NCT00839657
Association Between Genetic Variant Scores and Warfarin Effect
NCT03894878
PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care
NCT00377143
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
NCT01006733
Genetic Response to Warfarin in Healthy Subjects
NCT01520402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Randomized - Genetic
Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
Warfarin GenoSTAT Test
Use of genetic information from the GenoSTAT test to determine the warfarin dose
Randomized - Clinical
Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
No interventions assigned to this group
Registry
Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
Warfarin GenoSTAT Test
Use of genetic information from the GenoSTAT test to determine the warfarin dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Warfarin GenoSTAT Test
Use of genetic information from the GenoSTAT test to determine the warfarin dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Beginning warfarin (0 - 3 doses of warfarin taken at the time of enrollment) for a variety of diseases or conditions that require at least 30 days oral anticoagulation with target INR ≥ 2.0
Exclusion Criteria
2. A previous genetically determined warfarin dose
3. The treating physician does not agree to use the recommended warfarin dose or feels that the patient should not be enrolled in the study
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iverson Genetic Diagnostics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
An Pang Chieng, MD
Role: PRINCIPAL_INVESTIGATOR
Alhambra Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Veterans' Affairs Medical Center
Birmingham, Alabama, United States
Cardiovascular Consultants - Thunderbird
Glendale, Arizona, United States
Cardiovascular Consultants - Phoenix
Phoenix, Arizona, United States
Orthoarkansas
Little Rock, Arkansas, United States
Comprehensive Cardiovascular Specialists
Alhambra, California, United States
St. Joseph's Medical Center
Stockton, California, United States
Colorado Heart & Vascular
Denver, Colorado, United States
Okaloosa Heart & Vascular
Crestview, Florida, United States
Infinity-Northshore
Fort Lauderdale, Florida, United States
Infinity Clinical Research
Hollywood, Florida, United States
Heart Rhythm Specialists
Naples, Florida, United States
Sarasota Memorial Hospital
Sarasota, Florida, United States
Grady Hospital
Atlanta, Georgia, United States
Cardiology of Atlanta
Atlanta, Georgia, United States
Atlanta Heart Group
Decatur, Georgia, United States
Southern Heart Research Institute
Riverdale, Georgia, United States
St. Alphonsus Regional Medical Center
Boise, Idaho, United States
Rush University Medical Center
Chicago, Illinois, United States
Rockford Cardiovascular Research Foundation
Rockford, Illinois, United States
Carle Foundation
Urbana, Illinois, United States
Community Hospital Anderson
Anderson, Indiana, United States
St. Mary's
Evansville, Indiana, United States
Medical Consultants, PC
Muncie, Indiana, United States
NECCR
Falls River, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
Thoracic and Cardiovascular Institute
Lansing, Michigan, United States
Kansas City Heart Foundation
Kansas City, Missouri, United States
Cox Medical Center
Springfield, Missouri, United States
Billings Clinic
Billings, Montana, United States
Nebraska Heart Institute
Grand Island, Nebraska, United States
Nebraska Heart
Lincoln, Nebraska, United States
Alegent
Omaha, Nebraska, United States
Hackensack Medical Center
Hackensack, New Jersey, United States
New Mexico Heart Institute
Albuquerque, New Mexico, United States
Mission Hospital
Asheville, North Carolina, United States
Sanford Health Research
Fargo, North Dakota, United States
Aultman Hospital
Canton, Ohio, United States
The Christ Hospital
Cincinnati, Ohio, United States
Bend Memorial Clinic
Bend, Oregon, United States
Corvallis Clinic
Corvallis, Oregon, United States
Central Bucks Cardiology
Doylestown, Pennsylvania, United States
Palmetto Health Richland
Columbia, South Carolina, United States
Carolina Cardiology
Rock Hill, South Carolina, United States
St. Thomas Research Institute
Nashville, Tennessee, United States
Texas Cardiac Arrhythmia
Austin, Texas, United States
Nexxus Research
Bedford, Texas, United States
Legacy Heart Center
Plano, Texas, United States
Scott & White
Temple, Texas, United States
Providence Health Network
Waco, Texas, United States
Intermountain Medical Center
Murray, Utah, United States
Overlake Hospital
Bellevue, Washington, United States
Family Health Care of Ellensburg
Ellensburg, Washington, United States
Polyclinic
Seattle, Washington, United States
Swedish Hospital
Seattle, Washington, United States
Franciscan Research Center
Tacoma, Washington, United States
Marshfield Clinic Research Foundation
Marshfield, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IG-0109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.